Disquisitio, De immortalitate Animæ Scholastica

Quam ... Svb Præsidio ... Joh. Henr. Hottingeri ... Publico subjectam examini, pro virili, defendet. Franciscus Dasserius, GenevensisText teilweise hebräisch und griechischDissertation Hohe Schule Zürich 1666Dedikation an Odetus Lectius, Jacob Grenusius, Stephan Clericus, Theodor Tronchin, Philipp Mestresat und Franciscus Turretin auf Bl. A₁v. Gedichte von Felix Wyss, Johann Heinrich Hottinger f. und Andreas Wegelin auf Bl. C₂v

A phase Ib/II randomized, open-label drug repurposing trial of glutamate signaling inhibitors in combination with chemoradiotherapy in patients with newly diagnosed glioblastoma: the GLUGLIO trial protocol

Background: Glioblastoma is the most common and most aggressive malignant primary brain tumor in adults. Glioblastoma cells synthesize and secrete large quantities of the excitatory neurotransmitter glutamate, driving epilepsy, neuronal death, tumor growth and invasion. Moreover, neuronal networks interconnect with glioblastoma cell networks through glutamatergic neuroglial synapses, activation of which induces oncogenic calcium oscillations that are propagated via gap junctions between tumor cells. The primary objective of this study is to explore the efficacy of brain-penetrating anti-glutamatergic drugs to standard chemoradiotherapy in patients with glioblastoma. Methods/design: GLUGLIO is a 1:1 randomized phase Ib/II, parallel-group, open-label, multicenter trial of gabapentin, sulfasalazine, memantine and chemoradiotherapy (Arm A) versus chemoradiotherapy alone (Arm B) in patients with newly diagnosed glioblastoma. Planned accrual is 120 patients. The primary endpoint is progression-free survival at 6 months. Secondary endpoints include overall and seizure-free survival, quality of life of patients and caregivers, symptom burden and cognitive functioning. Glutamate levels will be assessed longitudinally by magnetic resonance spectroscopy. Other outcomes of interest include imaging response rate, neuronal hyperexcitability determined by longitudinal electroencephalography, Karnofsky performance status as a global measure of overall performance, anticonvulsant drug use and steroid use. Tumor tissue and blood will be collected for translational research. Subgroup survival analyses by baseline parameters include segregation by age, extent of resection, Karnofsky performance status, O6-methylguanine DNA methyltransferase (MGMT) promotor methylation status, steroid intake, presence or absence of seizures, tumor volume and glutamate levels determined by MR spectroscopy. The trial is currently recruiting in seven centers in Switzerland. Trial registration: NCT05664464. Registered 23 December 2022.</p

Energy System Integration (ESI) Platform 2014–2021

On the ESI platform (ESI stands for «Energy System Integration»), PSI, in collaboration with partners from industry and research, develops and demonstrates processes that enable a CO2-neutral energy system. The focus is on energy conversion processes that make additional biomass usable for the energy system, or render electricity from fluctuating renewable energy sources storable and accessible for other markets such as mobility on land, sea and air